(MedPage Today) – Washington – An investigational dual therapy has demonstrated antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase 2 SOLSTICE trial. At 24 weeks, the combined response to alanine…
Investigation group shows promising results in treating chronic hepatitis D